Log In
BCIQ
Print this Print this
 

AVX-470

  Manage Alerts
Collapse Summary General Information
Company Avaxia Biologics Inc.
DescriptionOral inhibitor of tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat inflammatory bowel disease (IBD); Treat pediatric ulcerative colitis (UC); Treat ulcerative colitis (UC)
Regulatory Designation U.S. - Orphan Drug (Treat pediatric ulcerative colitis (UC))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/05/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today